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INTRODUCTION 
 The second commonest cause of cancer in men and the sixth in the leading cases 
of mortality in the men internationally is the prostate cancer. The prostate  malignancy 
burden incidence is found  to grow to 1.7 million fresh patients in the world level and  
4,99, 000  fresh deaths can occur by 2030 just because of  the increasing growth and 
increase in  age of the global population (Ferlay et al., 2010)
2
. 
The prevalence of  prostate malignancy previously it was thought in India has been 
lower in incidence in comparison to those in west, but with an increase in the movement  
of village  population to the urbanised areas, changing individual life styles, increasing the 
knowledge  plus easy accessibility to the hospital facility, more number  of prostatic 
malignancies are being diagnosed and it is being of importance like that coming in the 
western countries. 
The national cancer registries give data which show that certain cancers are still 
increasing in incidence. The cancers showing increasing incidence include prostate, mouth 
and kidney in  the males. “Prostate the  second  leading site of cancer in the  males in 
studies conducted  in large Indian cities like Delhi, Kolkata, Pune and 
Thiruvananthapuram, and  third leading cancer site  in cities like Bangalore and Mumbai 
and  among the top ten of all  leading sites of cancers in  the population based cancer 
registries (PBCRs) of India
1
. The PBCRs at Bangalore (Annual Percentage Change: 
3.4%), Chennai (4.2%), Delhi (3.3%), Mumbai (0.9%) and Kamrup Urban District 
(11.6%) show a recording of statistically significant increasing values  in incidence rates 
over time”.1 
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“Despite earlier diagnosis and smaller tumor volumes, many of the patients with 
clinically organ confined prostate cancer, found to have extra prostatic disease subsequent 
to radical prostatectomy. Advanced staging are determined by Gleason score, serum PSA, 
and clinical staging. Of them Gleason scoring and PSA levels are the most important. 
Both serum PSA and Gleason scoring provide significant prognostic information 
as individual variables when their values are at the extremes”3. But, they cannot be used to 
assess the risk of progression and metastatic potential. Serum PSA levels have to be 
correlated with histopathological diagnosis, as it may be elevated in benign conditions and 
monitoring PSA levels help in identifying early secondaries in already diagnosed cases. It 
cannot help in assessing the risk of progression and metastatic potential of prostate cancer. 
Though Gleason score helps in grading and differentiating the tumor, exact 
assessment of risk for progression and metastatic potential cannot be made into well, 
moderate and poorly differentiated types. Molecular studies have to be correlated with 
elevated scores, like the present study.  With great advancements in biotechnology and 
molecular genetics, we are able to study the molecular behaviour of cancer genetics and 
metastases. 
“ E-cadherin is a calcium dependant cell adhesion molecule that determines 
development in the embryo and maintains adult differentiated epithelium and homeostasis. 
Aberrant or decreased expression has been reported to be associated with prostate 
carcinoma progression”.25 
VEGF, a potent angiogenic factor, playing an important role in tumor growth and 
metastases,  also has found to have increased expression  in prostatic malignancies when  
compared with normal appearing  epithelium or benign prostatic enlargement. Thus, 
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identifying such angiogenic factors responsible for prostate  malignancy growth and “ 
understanding their regulation will lead to the development of anti-angiogenic strategies 
useful for diagnostic studies and therapeutic interventions”31. 
The purpose of the study is to identify prostatic carcinoma with aberrant or 
decreased expression of E-cadherin and increased expression of VEGF for treatment 
strategies and to correlate these findings with PSA levels and Gleason scoring.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
AIM& OBJECTIVES 
 
4 
 
AIM AND OBJECTIVES 
AIM   
    To study the value of expression of   E-cadherin and Vascular Endothelial Growth 
Factor Immunohistochemical markers in the prostatic carcinoma specimens, received and 
diagnosed in the Department of Pathology, Coimbatore Medical College. 
OBJECTIVES 
 To find out the incidence of prostatic carcinomas among CMCH patients 
 To study the clinical presentation of prostatic cancers 
 To study the expression of E-cadherin and VEGF in prostatic carcinomas 
 To study the implication of loss of E-cadherin expression in prostatic carcinomas 
 To study the correlation between Gleason scoring and PSA values in prostate 
carcinomas 
 Correlation of E-cadherin expression and VEGF expression in prostatic cancer 
biopsies  with Gleason scoring 
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REVIEW OF LITERATURE 
A small retroperitoneal accessory sex gland located around the neck of bladder and 
urethra is the prostate gland.  Measuring 4cm in width, 3cm in length and 2 cm in depth  
the organ weighs about 20 grams. Urethra that leaves the bladder and passes through the 
prostate gland is called the prostatic urethra. A transitional epithelium lines the lumen of 
the crescent-shaped prostatic urethra. 
The urogenital sinus in the third month stimulates the differentiation of the 
prostate. Dihydrotestosterone drives   development of prostate as five epithelial buds on 
the posterior aspect of urogenital sinus, in pairs. The top pair of buds from the mesoderm 
forms the inner zone of prostate and the lower buds from the endoderm form the outer 
zone of prostate. This development forms the basis of pathology behind the occurrence of 
benign prostate hyperplasia in the inner zone and prostate carcinoma in the outer zone. 
Arborization into the urethra forms the acini and collecting ducts in the prostate. 
The surfaces of the prostate are lateral, posterior and anterior. There is an apex in 
the inferior aspect and broad base in the superior aspect contiguous with the bladder base. 
The prostate has a capsule made up of collagen   elastin and, plenty of smooth muscle 
fibres. 
Structure 
The parenchyma of   prostate comprises of glandular elements making 70% and 
fibromuscular stroma making 30%. The stroma is made up of collagen and smooth muscle 
bundles, which blends to form the capsule. The contractile effect of the stroma encircling 
the glands aids in the expulsion of secretion from the gland during the process of 
ejaculation into the urethra. 
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The prostatic gland is made up of small, branched tubuloacinar glands. Some of the 
prostatic glands contain solid secretory aggregations called prostatic concretions, within 
their acini. The prostatic concretions appear as small red dots.      
The glandular epithelium varies from simple cuboidal or columnar to 
pseudostratified epithelium.  A longitudinal urethral crest of dense fibromuscular stroma 
without glands, widens in the prostatic urethra to form a smooth domelike structure called 
the colliculus seminalis. In the middle of the colliculus seminalis,  is a cul-de-sac called 
the utricle. Two ejaculatory ducts open at the colliculus, one on each side of the utricle. 
Underlying  the epithelial cells, are flat basals cell  lining  each of the  acinus, which give 
rise to the secretory epithelium acting as stem cells. 
Organizational Topography of the Adult Prostate 
 Literature review shows there has been considerable workup in relating the origin 
of major prostatic diseases to specific sites of predilection within the organ. Traditionally, 
the topography of disorders of prostate is connected to prostate lobes. After lot of research, 
the concept of “zones”, has replaced the “lobes” of prostate. 
Studies underwent in prostate morphology in the 19th century reported that, the 
adult prostate is made of four lobes: two lateral lobes, a middle lobe, and an anterior lobe, 
which is inconstant. In the year 1912, Lowsley 
5
 has described an additional “posterior 
lobe” in the studies of prostate development he made, in the fetus. In the years following, 
the existence of the five fetal  prostate lobes, has been extended  to the clinical study of 
diseases of the adult prostate. However, the division of these lobes in the adult prostate has 
come under increased questioning in later anatomic studies.  
7 
 
Franks has described three groups of ducts distributed in the adult prostate as 
“inner zone” and a surrounding “outer zone.” The outer zone in the prostate has long ducts  
which are branching, and the inner zone has short, simple mucosal and the submucosal 
glands in the urethra. The inner zone has been reported to be the exclusive site for nodular 
hyperplasia, and its location has corresponded to the region reported as responsive to the 
estrogens. The outer zone was the site of origin of prostatic adenocarcinoma.                  
McNeal
5
, in his most studies done recently, employed serial sections of the adult 
Prostate, done  in a coronal plane, identified a different organizational pattern of the adult 
prostate.   Five regions histologically identified in the prostate have been described. The 
zone that is anterior is composed of principally, of  a few glands with fibromuscular 
stroma.  The peripheral zone, which is roughly equivalent to Lowsley's lateral and the  
posterior lobes, consists of approximately 75% of the glandular component of the prostate. 
This peripheral zone is characterized by simple glands and loosely arranged stroma 
and is the commonest site of origin of most of the  prostatic adenocarcinomas. A central 
zone   is located between, and that surrounding the ejaculatory ducts, as they are coursing 
to the verumontanum from the prostate base. This central zone constitutes of 
approximately 20% of the prostate and approximates that of Lowsley's middle lobe. 
The periurethral glands are located within a sheet of the muscular internal urethral 
sphincter. This part of the urethra (proximal to the verumontanum) has been called the 
preprostatic urethra, and comprises, the fourth zone. The fifth zone, which is the 
transitional zone, constitutes glands, that terminate into the distal preprostatic urethra and 
thereby, grow laterally around the distal end of the internal urethral sphincter. This region 
is lying anterior to the central zone and medial to the peripheral zone.  Most of the 
hyperplastic nodules originate in this transitional zone. 
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Rarely, nodular hyperplasia can also be observed in the peripheral zone. 
Blacklock
5
 in his studies, has confirmed the essential structural features of the adult 
prostate as that was originally reported by McNeal. 
 Epidemiology 
The subject of numerous ongoing studies and reviews has been the epidemiology 
of prostate. The effect of age, race, social customs, religion and geography on the 
occurrence of this malignancy, has been extensively studied.  United States, show the 
maximum incidence of prostate carcinoma in American males, which has exceeded the 
prevalence of the leading lung carcinoma in 1990.
6
 
Age 
Prostate carcinoma has been a disease of men, in the elderly age group. Patients 
younger than 50 years, comprise approximately, 1% of all cases of prostate carcinoma, 
diagnosed in the United States. Uncommon, were those cases, involving men younger than 
age 30 years. Seventy-five percent of patients with prostatic carcinoma were belonging to 
the age-group of 60 to 75 years. The frequency of cases of prostatic carcinoma diagnosed 
at autopsy (latent carcinoma) shows the progressive increase as age increases. 
Following the introduction of serum PSA screening, there has been significant 
impact in the incidence of carcinoma prostate. The detection of prostate cancer in 
asymptomatic patients with serum PSA showed a sudden rise in the incidence of prostate 
cancer. This increase was due to the early identification of those harbouring “latent” 
cancers and there was a decrease in incidence. 
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Etiology 
Years back, studies involving the finding of causes of prostate cancer have been 
centred on environmental, dietary, endocrine and till recently, genetic influences. The 
racial and geographic differences tell that any of these influences upon the causation could 
be operative.  The established role of testosterone in the growth of normal prostate has led 
to the point that endocrine factors are among the etiological causes in the progression of 
prostate cancer. The  absence of both benign  hyperplasia of prostate and malignancy  of 
prostate in men castrated before puberty, in contrast to the  post pubertal castration and the 
responsiveness of the primary and metastatic prostatic carcinomas to the therapeutic 
castration and exogenous estrogen as that was originally described by Huggins and 
Hodges.
6
 Even after considerable researches, the empiric observations made are not  
understandable or the role of hormones in leading to prostate carcinoma causation. 
 Clinical Presentation 
The clinical occurrence of prostate carcinoma is seen as a spectrum of 
unsymptomatic patients, and patients presenting with local signs and symptoms and 
patients with distant metastases. The cancer in these patients  have historically been 
categorized into incidental cancers, clinically symptomatic cancers, and occult cancers, 
respectively. 
Asymptomatic Patients with incidental prostatic carcinomas 
The diagnosis of prostatic carcinoma is an incidental finding  in both TURP that 
was removed for symptomatic nodular hyperplasia and cystoprostatectomy specimens 
which are removed for bladder carcinoma as well as an  incidental discovery at autopsy 
who are without any  prior clinical evidence of prostate carcinoma. The utilization of the 
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tumor marker PSA, has led to the finding of patients harbouring this malignancy, 
prompting the diagnostic needle biopsies. 
 Studies have reported the frequency of incidental prostatic carcinomas in simple 
prostatectomy and TURP specimens that are obtained for clinically benign disorders 
(BPH)  as to range from 3% to 24% with an average of 9.2%.
6
  
 Finding  prostatic carcinomas in asymptomatic patients who harbor either a 
palpable mass or a radiologic abnormality in the prostate, but  have abnormal serum PSA 
levels (T1c) indicating them  to do diagnostic needle biopsy, has become the most 
common clinical presentation of prostate  malignancy. In asymptomatic patients with a 
nodule detected by Digital examination, prostatic carcinoma was diagnosed by needle 
biopsy in the pre-PSA era.  The frequency of patients with symptoms from local spread of 
the primary tumor is less common, and least are those presenting with distant bone 
metastasis.  
Clinical Presentation with Metastases 
 Very rarely patients coming with problems related to distant metastases as the 
initial symptom. Those prostatic cancers termed as occult carcinomas with clinical 
presentation of distant metastases has significantly decreased in incidence during the last 
half century and still continues to decline. Examples of patients who are initially 
presenting with metastatic deposits to lung, skin, supraclavicular lymph nodes, brain, 
intraorbital, abdominal and retroperitoneal sites, are recorded in literature.  
Symptoms of local disease 
 The presenting symptoms were urinary complaints or related to retention, back 
ache, and  hematuria in the pre-PSA era. The availability of PSA screening has made most 
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prostate cancers to be diagnosed at an early asymptomatic stage in the current state. When 
problems related to urinary tract do occur, then conditions other than prostate cancer must 
be thought of, like increased urinary frequency, unavoidable  urgency and decreasing urine 
stream can result even from benign hyperplasia of prostate. 
Symptoms of advanced stage 
Lymphatic, haematogenous, or contiguous local spread can present in advanced 
stage of prostate cancer. Bone symptoms are very common, as this prostate tumor  has the 
strong capability for metastasizing to the bone. 
 Metastases and advanced stage  prostate cancer can manifest as 
Anaemia, loss of weight and  appetite loss, 
“Bone pain, that can present with or without pathologic fracture 
Neurologic deficits resulting from spinal cord compression 
Lower extremity oedema seen due to the obstruction of venous and the lymphatic 
tributaries by nodal metastasis. 
Uremic symptoms occurring from ureteral obstruction that is caused by local 
prostate growth or that from retroperitoneal adenopathy, leading secondarily to nodal 
metastasis hematuria, pain.  
Ureteric and/or bladder outlet obstruction, Urine retention symptoms, Chronic 
renal failure, 
 Urinary incontinence and symptoms that are related to bone or soft-tissue 
metastases 
12 
 
Physical examination of patient alone cannot help us to differentiate benign 
prostatic disease from the cancer. Therefore, a biopsy is warranted to establish the 
diagnosis. But still, false-negative results do often occur; therefore multiple biopsies may 
be required before prostate cancer has been diagnosed”.5,6 
If a malignancy is suspected, then determining whether cancer is localized or is 
extending outside the capsule is very important for planning the treatment. When the 
lateral sulcus is obliterated or if the seminal vesicle is involved it often indicates a locally 
advanced disease.
 
When patients present with advanced disease they may have the following: 
Bone tenderness, Cancer cachexia, Lymphedema of lower extremity or deep 
venous thrombosis, lymphadenopathy, distended bladder cause by outlet obstruction 
Possible spinal cord compression must be excluded by doing neurologic 
examination, like determination of external anal sphincter tone.   
Diagnostic Procedures 
1. Digital Rectal Examination 
Digital Rectal Examination has been the most important method of detecting 
prostatic carcinomas in  pre PSA era. The utility of digital examination remains an 
integral component of the urologist's panel of diagnostic armamentarium, currently which 
is combined with serum PSA and other radiologic procedures, especially ultrasound. 
2. Serum Markers 
A spectrum of various serum tumor markers have been utilised in the diagnosis and 
further treatment of prostate carcinomas including PSA, and prostate-specific membrane 
13 
 
antigen (PSMA). PAPs, which were previously utilized extensively, have limited 
contribution nowadays, being eclipsed by still more sensitive marker like PSA. Another 
marker, reverse transcriptase-polymerase chain reaction (RT-PCR) which was introduced 
in the early 1990s, continues to be still plagued with other methodological complications 
but currently limiting its clinical utility. 
Prostate-Specific Antigen 
PSA, a single  stranded glycoprotein (serine protease) having 237 amino acids 
encoded by a gene in the chromosome 19.
7
 The  molecular weight of PSA is 34 kd.
8
  PSA 
is being produced by the  prostate lining epithelial cells of  all normal, hyperplastic and 
even neoplastic glands. Also ectopic prostate tissue, prostate glands in male and urethrae 
also produce PSA.  Any location, the production is being controlled by  androgens. PSA 
circulates in a complexed form in blood and serum with α-antichymotrypsin (80%) or  a 
free or as inactive form (20%).
8
 
Many large studies from 1987 to1989 have used serum PSA as a clinical marker 
for detection and postoperative monitoring of prostate cancer.  Following the introduction 
and initial clinical utility of serum PSA Values, further effect of patient age, and the 
concurrent prostate pathology were evaluated to highly refine interpretation of the PSA 
values. This has led to the establishment of  an age-related baseline for those  patients in 
their  sixth decade through their ninth decade .Though,  serum PSA unassociated with 
prostate carcinoma, increased during this age from less than 2.5 ng per mL to 6.5 ng per 
mL,9 and therefore there is a need to set the “normal baseline values” of serum PSA.  
Moreover, elevations of serum PSA were also seen in acute prostatitis, nodular 
hyperplasia of prostate, BCG therapy prostatitis and other diagnostic procedures like 
14 
 
digital examination, needle biopsy and even cystoscopy.
10
  Such  elevations of PSA 
following diagnostic events were transient. But this elevation seen in non-neoplastic 
prostate disorders has variably prolonged values, and is amenable to appropriate therapy. 
Non-prostatic lesions resulting in elevated serum PSA levels have been reported in very 
rare cases of renal cell carcinoma.
11
 
Such multiple influences relating to the serum total PSA levels has diminished the 
sensitivity of this as a tumor marker. So this is particularly true with the current patient 
population, of whom many, harbor small-volume asymptomatic prostate carcinomas. 
 Thus the major contribution to the serum PSA levels reflect their concomitant 
volume of associated nodular hyperplasia. The result is that those  patients having 
prostatic carcinoma are found to have serum PSA levels of 1  to 3 ng per mL, which is 
significantly below  empirically derived value of 4 ng per mL cut off level.
12 
Additional 
variants of the  PSA assays are being  introduced to address such  limited sensitivity, like 
the ratio of free is to the total serum PSA,  prostate  specific antigen density (PSAD), and 
prostate  specific antigen density velocity (PSAV) which are attempting  to increase the 
value of  serum PSA measurements in selectively showing the risk of prostate 
carcinoma.
11
 
                       Ratio of Free-to-Total Prostatic- Specific Antigen 
                       Prostate - Specific Antigen Density 
                       Prostate - Specific Antigen Velocity 
                       Prostate - Specific Membrane Antigen 
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3. Radiologic Studies include 
               Ultrasound 
              Computerised tomography 
              Magnetic resonance imaging 
               Radionuclide bone scan 
3. Prostate Needle Biopsy: Biopsy Protocols followed: 
Needle biopsies that were done before the introduction of the sextant biopsy 
procedure in the year 1989 were “directed biopsies.” Biopsies obtained from prostate 
nodules was by palpating the gland digitally. The first ever systematic biopsy protocol has 
been introduced by Hodges and associates in the year 1989 with the idea of identifying 
various  prostate lesions that were located  in the six quadrants of prostate, three on the 
left side and three on the right side, sampling the base of prostate,  midprostate and 
apex.
13
 This procedure has been called the sextant biopsy protocol, wherein a significant 
improvement  was achieved in the diagnostic yield when  compared to the previously 
employed directed biopsy procedures 
Predictive Value - Prostate Needle Biopsies 
Many times the information derived from the prostate needle biopsy findings will 
extend beyond the primary purpose of the biopsies— diagnosis of prostate malignancy. 
The Gleason scoring, number of positive biopsies,  tumor volume in the taken  needle 
cores, and the possible  presence of perineural invasion are  having predictive value and 
thus contributing to individualizing the patient’s therapy protocols. 
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Gleason Grading. 
 Among all of the proposed grading protocols, in the years, only the Gleason 
grading system which was introduced in the year 1966 has emerged to achieve a 
worldwide acceptance during the recent years. Exclusive of  tumor staging, it is a more 
morphologic parameter that has proven  prognostic value. The Gleason scoring of the 
tumors identified in needle biopsies have demonstrated more value in the pretherapy 
prediction of capsular penetration, the seminal vesicle involvement, positive margins, 
pelvic lymph nodal  metastases, post therapy biochemical failure and cancer-specific 
survival following definitive therapy
14,15
. Cumulative experience have demonstrated that 
most of the  prostate carcinomas have Gleason scores ranging from 5 to 7, with less than 
10%  having Gleason scores 2 to 4, and nearly 20%  from 8 to 10. 
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Microscopical examination of  the biopsy specimen is done for  assessing  the "Gleason  
patterns. These Gleason patterns have the following features: 
Pattern 1 - The cancerous gland closely resembles normal prostate tissue. The 
glands are all small, well-formed and closely packed. This correlates to a well 
differentiated carcinoma. 
Pattern 2 - The tissue has still well-formed glands, but  are larger and have more 
tissue in between them, implying that  stroma has increased. This also correlates to a 
moderately differentiated carcinoma. 
Pattern 3 - The tissue has still recognizable glands, but these cells are darker. At 
higher magnification, some of the tumor cells have left the glands and are seen to invade 
the surrounding tissue or have an infiltrative pattern. This also correlates to a moderately 
differentiated carcinoma. 
Pattern 4 - The tissue has only few recognizable glands. Many cells are seen 
invading the surrounding tissue as neoplastic clumps. This correlates to a poorly 
differentiated carcinoma. 
Pattern 5 – There are no or only a few recognizable glands. They are often just 
sheets of cells throughout the surrounding tissue. This correlates to an anaplastic 
carcinoma. 
In the present Gleason system, prostate cancer of Gleason patterns 1 and 2 are very 
rarely seen. Gleason pattern 3 is the most common.
16 
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Primary, secondary and tertiary grades 
The tissues are then assigned a grade based on the observed patterns in the 
specimen. 
Primary grade is assigned to the dominant pattern of the tumor that has to be 
greater than 50% of the pattern seen. 
Secondary grade is assigned to the next-most frequent pattern that has to be less 
than 50%, but, at least 5%, of the pattern of the total cancer observed. 
Tertiary grade is where there is a small component of a third (generally more 
aggressive) pattern. 
Scores and prognoses 
Then the pattern-number of the primary and secondary grades are summed up to 
obtain the final Gleason score. If only two patterns are identified, then the  first number of 
the score is  the tumor's  primary grade,  while the second is that of the secondary grade. If 
three patterns are identified, then the  first number of the score would be that of  the 
primary grade and the second number,  pattern with that of the  highest grade. For 
example, if the primary grade of the tumor was 2 and the secondary tumor grade was 3, 
but still some cells were found to be grade 4, then the Gleason score would be 2+4=6. So 
this is a slight change from the pre-2005 Gleason system, where the second number, was 
the secondary grade (i.e., the grade of the second-most common cell line pattern).
16 
Gleason scores can range from 2 to 10, with 2 being the most well-differentiated 
tumors  and 10 the least of differentiated tumors.  Gleason scores have been categorized 
into groups, showing similar biologic behaviour as low-grade (well-differentiated), 
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intermediate-grade, moderate to poorly differentiated or high-grade. More recently, an 
investigation of the Johns Hopkins Radical Prostatectomy Database (1982-2011) leads to 
the following proposed reporting of Gleason grades and prognostic grade groups
17
:
 
Gleason score ≤ 6 (prognostic grade group I); 
 Gleason score 3+4=7 (prognostic grade group II);  
Gleason score 4+3=7 (prognostic grade group III); 
 Gleason score 4+4=8 (prognostic grade group IV); 
 Gleason scores 9-10 (prognostic grade group V).
17 
 Prostate cancers with a Gleason score ≤ 6 usually have rather good prognoses”.14,15,16 
When the biopsy of prostate tissues are examined and graded using Gleason 
scoring, it gives us an idea about the malignant nature and also corresponds with the 
pathological staging, which is the same with serum PSA values. “ Both these factors- 
serum PSA and Gleason’s score provide significant prognostic information as individual 
variables, when their values are either very high like(PSA level>20ng/ml; Gleason 
score>8)
18
 or in the lower end like(PSA level<4 ng/ml; Gleason score2-4) of the spectrum. 
However not with  most of the patients presenting with intermediate PSA levels and 
Gleason scores. Recently, following several studies, several groups have combined clinical 
staging, serum PSA levels and Gleason’s scoring to generate certain “normograms” that 
are useful for prediction of  pathological staging or assessing the prognosis”.19 Although 
all these efforts help us in making a general estimate of prognosis that can be made with 
the readily available clinical data, they do not help in predicting the  accurate disease, 
outcome of each  individual patient’s,  prostate cancer. 
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Latest techniques in molecular biology has helped us in understanding the 
metastatic or aggressive potential of various cancers and the tumor – host interaction 
necessary to produce symptomatic metastases.
20
 Thus inability to produce a metastasis can 
be the result of different single or multiple defects in this cascade.
 
Studies by Hiroki Kuniyasu et al applied calorimetric ISH technique to study “ the 
expression level of several genes that regulate particular steps of metastasis in human 
prostate cancer cells implanted into the prostate of nude mice3. Highly metastatic cells 
showed higher expression of  mRNA levels of type IV collagenase, basic fibroblast 
growth factor and interleukin 8 that are affecting angiogenesis.
3
 No difference in 
epidermal growth factor receptor expression was found between the cells, but the 
expression of E-cadherin was decreased in the metastatic cells. VEGF/VPF(vascular 
permeability factor), which affects tumor angiogenesis has also been found to be 
overexpressed in prostate cancer in comparison with normal epithelium or benign 
hyperplasia of prostate”.3 
It was found by the researchers that  microvessel density can be assessed by 
VEGF/VPF levels.
22
There are various studies that has “evaluated the expression of   E-
cadherin, type IV collagenase and  microvessel density in human cancers as single 
prognostic factors.
23 
Almost all these studies have given the final conclusion that the 
expression of a given gene is necessary but insufficient to account for the multistep 
process of metastasis”.24 As  each one of the “discrete steps in the pathogenesis of 
metastasis is regulated by one or several independent genes, the  identification of  those 
cells with metastatic potential  in that of heterogenous primary human prostate cancer 
requires multiparametric, multivariate analysis of the gene expression. Thus the study 
conducted by Hiroki KUNIYASU ET al showed that  increased expression of collagenase 
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type IV, VEGF/VPF and decreased expression of E-cadherin are associated with 
increasing Gleason’s score”.3  
E-CADHERIN 
Cadherins are a group of “ type-1 transmembrane proteins. They play very 
important role in the process of cell adhesion, forming adherens junctions to the binding 
cells, within tissues. They are dependent on calcium ions to function, hence they get their 
name. Cell-cell adhesion is being mediated by extracellular cadherin domains, whereas 
those of  the intracellular cytoplasmic tail associate with a large number of adaptor and 
signaling proteins, which are collectively referred to as the cadherin adhesome”.25 
  The calcium dependant adhesion factor E-cadherin, whose gene is present in 
chromosome 16q22, is present in most of the normal epithelium, helps in the formation of 
glands, layering and polarisation. Abnormal epithelialisation, less differentiation showed 
more aggressive and invasive cancers.  Thereby reduced expression of E-cadherin was 
observed in the aggressive tumors of the esophagus, ovary and the stomach.  “Mechanisms 
by which the expression of E-cadherin protein is lost would include E-cadherin gene 
mutation and the loss of the wild-type allele by the loss of its  heterozygosity. These 
studies indicate that E-cadherin is a classical tumor suppressor gene”.2 
The functional role of E-cadherin in tumor progression was studied following the 
frequent loss of E-cadherin in most of the malignant tumors in various studies. The forced 
expression of E-cadherin  using  tumor cell lines in culture, it was demonstrated by various 
studies  that “ re-establishing  the functional cadherin complex,  resulted in a reversion 
from an invasive to the  benign, epithelial cell phenotype”.27  
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Several of these experiments have clearly demonstrated that there has been  a 
prima  role for the  E-cadherin in suppressing  the invading tumor  in the cultured cells. 
However, it has remained still elusive if  the absence  of E-cadherin permissible cell 
adhesion has been a prerequisite for the development  of  tumor or if  it has been  the result 
of the consequence of de-differentiation in  the process of  tumor development.
28
  It has 
recently been  revealed  that the  expression of Ecadherin will be absent in the 
transformation from a  well differentiated tumnor like  adenoma to the more invasive 
carcinomas in the studies in the mouse,  transgenic  model of  β-cell tumorigenesis in the 
pancreas (RIP1TAG2). It was noted that there was an stoppage of tumor development  at 
the adenoma stage, when there was e-cadherin presence persistent by β cell 
tumorigenesis.
29
 
But in contrast, there was early invasion and metastasis with genotype of a 
dominant negativity of E-cadherin. Thus, these studies demonstrate that when there is a      
“loss of E-cadherin mediated cell-cell adhesion which, is one of the rate-limiting steps 
from the progression of adenoma to carcinoma in vivo and it will highlight the role of E-
cadherin, as a suppressor of tumor invasion. Normal epithelium is being organized by a 
number of specific intercellular tight junctions, adherens-type junctions, and desmosomes, 
which are then intimately interconnected with the actin and intermediate filament, 
cytoskeleton”. 29 
VASCULAR ENDOTHELIAL GROWTH FACTOR 
MOLECULAR BASICS OF THE TUMOR ANGIOGENESIS IN THE PROSTATE 
CANCER 
 As per the study named “ VEGF Inhibitors and Prostate Cancer Therapy by 
Jeanny B. Aragon-Ching, and William L. Dahut,
30
 the recent concept of angiogenesis 
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inhibition, as a novel anti-cancer treatment strategy has emerged with the observation that 
neovascularization is very much required in order to sustain the expansile growth for all 
the solid tumors.
31
 One method of analysing the process of neovascularizaton is the 
measurement of endogenous proteins that are involved in the angiogenic cascade, that  
includes basic fibroblast growth factor (bFGF), VEGF,  platelet-derived growth factor 
(PDGF), among others. Other methods of evaluating the process of neovascularization 
include histological studies which look at microvessel density (MVD) by staining the 
endothelial cells with antibodies that are directed to Factor VIII, CD34 or CD31 and 
determining the mRNA, protein or the receptor expression”.32 
It has also been studied that assessing the small vessel density will help in creating 
newer chemotherapeutic strategies against angiogenesis to arrest cancer advancement.
33
 
THE SIGNALING PATHWAY OF VEGF 
Angiogenesis mediated by VEGF signalling pathways, represented by seven 
polypepetide growth factors regulating the tyrosine kinases have two receptors in the 
endothelial cells helping in the cell proliferation.
34
 
CLINICAL STAGING 
TNM AJCC STAGING PROTOCOL FOR PROSTATE ADENOCARCINOMA 
(2002) 
“ Primary Tumor (T) 
 TX  Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
 T1 Clinically inapparent tumor not palpable nor visible by imaging 
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 T1a Tumor incidental finding in 5% or less of tissue resected 
 T1b Tumor incidental finding in more than 5% of tissue resected 
 T1c Tumor identified by needle biopsy (eg, because of elevated PSA) 
 T2 Tumor confined within the prostate* 
 T2a Tumor involves one half of one lobe or less 
 T2b Tumor involves more than one half of one lobe but not both lobes 
 T2c Tumor involves both lobes 
 T3  Tumor extends through the prostate capsule** 
 T3a Extracapsular extension (unilateral or bilateral) 
 T3b Tumor invades seminal vesicle(s) 
 T4 Tumor is fixed or invades adjacent structures other than seminal vesicles: 
Bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall 
 *Tumor found in one or both lobes by needle biopsy, but not palpable or reliably 
visible by imaging, is classified T1c. 
 **Invasion into prostatic apex or into (but not beyond) the prostatic capsule is 
classified not as T3 but as T2
35 
 PATHOLOGIC STAGING 
 Primary Tumor (T) 
 pT2*  Organ confined 
 pT2a  Unilateral, involving one half of one lobe or less 
 pT2b  Unilateral involving more than one-half or one lobe but not both lobes 
25 
 
 pT2c  Bilateral disease 
 pT3   Extraprostatic extension 
 pT3a  Extraprostatic extension** 
   **Positive surgical margin should be indicated by an R1 descriptor (residual 
microscopic disease). 
 pT3b  Seminal vesicle invasion 
 pT4  Invasion of urinary bladder, rectum 
  *There is no pathologic T1 classification. 
 Regional Lymph Node Metastases (N) 
 pNX  Regional lymph nodes not examined 
 pN0  No regional lymph node metastasis 
 pN1  Metastases in regional lymph node(s) 
 Distant Metastases (M) 
 pMX  Distant metastasis cannot be assessed 
 pM0  No distant metastasis 
 pM1  Distant metastasis 
 pM1a  Nonregional lymph node(s) 
 pM1b  Bone(s) metastasis 
 pM1c Other site(s) of metastasis Metastatic Prostatic Carcinoma—pN, pM 
Histopathologic grade (G) 
GX Gleason score cannot be assessed 
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Gleason ≤ 6 Well differentiated (slight anaplasia) 
Gleason 7 Moderately differentiated (moderate anaplasia) 
Gleason 8-10 Poorly differentiated or undifferentiated 
Whitmore-Jewett staging 
The Whitmore-Jewett system which is similar to TNM system, has approximately 
the  equivalent stages.  
A: tumor  present, but is not detectable clinically; only found incidentally 
A1: tissue mimicks normal cells, found only in a few chips of one lobe 
A2: extensive, involvement 
B:  tumor  felt on physical examination, but  not spread outside prostatic capsule 
B1: tumor is felt and not involving whole lobe 
B2: tumor is felt and  occupies whole lobe or both of  the lobes 
C:  tumor extending through  capsule 
C1: tumor extending  through capsule, not involving the seminal vesicles 
C2: tumor involving  seminal vesicles 
D:  tumor  spreading to other organs 
The definition of stage D by Whitmore-Jewett has been further stratified by 
Crawford and Blumenstein. The additional stratification is thought to improve 
classification and understanding of a subset of patients who have hormone-insensitive 
prostate cancer. 
 
27 
 
The staging is as follows: 
Stage D1 - Involvement of pelvic lymph nodes 
Stage D1.5 - Rising PSA level after failure of local therapy (ie, biochemical 
failure) 
Stage D2 - Metastatic disease to bone and other organs 
Stage D2.5 - Rising PSA after nadir level 
Stage D3 - Hormone-refractory prostate cancer 
Stage D3.5 - Sensitive to hormones 
Stage D4 - Insensitive to hormones”36 
Prostatic carcinoma with metastases has been encountered in a wide range of  
spectrum of clinical circumstances. Very rarely, patients present initially with symptoms 
that are referable to distant sites of metastases without any prior clinical evidence of a 
prostatic primary.
82
 More often, metastases are being discovered only at the time of 
prostatectomy or usually subsequent to the definitive therapy. Moreover, multiple studies 
have documented the various patterns of metastasis found at autopsy.  Prostatic 
adenocarcinoma with metastases has been assigned stages pN or pM.
37 
The natural progression of prostatic carcinoma usually involves the initial 
dissemination to the regional pelvic lymph nodes. The most common initial site of tumor 
dissemination, being the obturator nodes and the other pelvic nodes,  including the iliac 
and the sacral lymph nodes.
38
 Very rarely, periseminal vesicle lymph node and 
periprostatic  metastases have also  been reported, which have been staged as pN1. Other 
distant lymph node metastases which include para-aortic, the common iliac, the inguinal, 
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the retroperitoneal, the supraclavicular and the cervical nodes can also harbor metastases 
and are classified as pM1a.
 
The identification of pelvic lymph nodes metastases by  Pelvic lymphangiograms 
and MRI was found to be less sensitive and specific to accurately contribute to the 
identification of possible metastases, but  frozen section done  before or during  the time of 
radical prostatectomy has  increased both the sensitivity and specificity. 
 
But, enough cumulative knowledge about the risk of  pelvic node metastases has 
allowed that those patients with prostate Gleason scores 6 or less and that of  PSA less 
than 10 ng per mL were found to  have a risk of less than 5% positivity of pelvic nodes.
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Thus, determination by this method exceeds the sensitivity of that of intraoperative frozen 
section diagnosis of pelvic nodal deposits and the same “nomogram” approach has been 
currently adopted to select those  patients with significant risk of pelvic node metastases 
and those  who would thereby benefit from the  node excision done at the time of 
prostatectomy. 
Lymph node metastases, usually at diagnosis have been found to be  less than 1 cm 
in diameter in the  majority of the cases, with many others presenting as micrometastases 
i.e.less than 2 mm. Exact  diagnosis nowadays have  often been assisted with 
immunohistochemical staining for PSA. At the same time, those patients with larger 
metastases in the  pelvic nodes, it was found that  both the tumor volume (measured 
diameter) and the number of the  positive lymph nodes were significantly related to the  
risk of tumor progression. Metastases with extranodal extension of tumor clearly, does not 
elevate the risk of progression, when studied  by multivariant analysis.
40
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In the clinical perspective of prostate adenocarcinoma, we must be aware of other 
possible concurrent malignancies that can  involve the pelvic lymph nodes including those 
of malignant lymphoma and metastatic urothelial carcinoma of urinary bladder origin, 
must also be excluded. 
 Bone metastases, which are characteristically osteoblastic, have been found to be 
the next most frequent site of prostatic carcinoma dissemination and have been assigned 
the stage category of  pM1b. Pelvic bones, vertebrae and ribs are found to be the most 
common bones to harbour the  metastatic deposits, at autopsy. Multiple osseous sites have 
been  documented in some other cases.
83
 Bone metastases that  have been detected  with 
radionuclide bone scans, were found to be more significantly  sensitive and specific than 
the bone radiographs.  
Basically, the priority for vertebral metastases has been regarded as the result of 
spread through perineural lymphatics and  that of  Batson's plexus, the valveless vertebral 
venous plexus. But the same was later studied and it was concluded, that was not true, and  
of bone metastases from prostatic carcinoma found to be similar to those  of other 
nonprostatic malignancies.
41
 The reasons for the  prostate cancer metastases for 
developing  in the skeleton have recently been elucidated: 
 (1)The Metastatic tumor cells releasing humoral factors, like parathyroid hormone 
and interleukin 6, can  induce  more osteoclastic assembly and their differentiation. 
(2)  “Prostatic cancer cells can concomitantly produce many soluble paracrine 
factors like transforming growth factors and insulin-like growth factor. 
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(3) The Osteoclastic activity further  releases growth factors like transforming 
growth factor-β that can  stimulate the tumor growth, thus initiating the vicious cycle of 
excess bone resorption. 
(4)The Osteoblastic activation, in turn releases the  unidentified osteoblastic 
growth factors, that can  also stimulate further  tumor cell growth, thus  contributing to a 
cycle of abnormal bone formation  
Metastases can involve bone by means of the proposed 3 main mechanisms: (1) by  
direct extension, (2) by retrograde venous flow, and (3) by seeding as tumor emboli within 
the blood circulation.
42
 Seeding  ususally occurs initially in the red marrow; which is the 
cause for the predominant distribution of the metastatic lesions, in the red marrow–
containing areas, in the  adults. But in contrast, usually widespread  bone metastases are 
seen in children. Retrograde venous embolism has been the major mechanism of spread 
from the  intra-abdominal cancer involving  the vertebrae. Increase in intra-abdominal 
pressure can cause blood to be diverted from that of  the systemic caval system to those of  
the valveless vertebral venous plexus of Batson;
43
 thus  allowing the caudal and cranial 
flow of blood. When  a metastatic lesion grows into the medullary cavity, the surrounding 
bone is usually remodeled by  either osteoclastic or osteoblastic processes. The degree of  
bone resorption or deposition varies generally and depends on the type and location of the 
tumor”.41,42 
The association among the osteoblastic and osteoclastic remodeling methods, will 
determine if , there is going to be  a predominantly  lytic, blastic, or mixed pattern being 
seen on the radiographs.  
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Lung metastases have been the third most common site of prostatic carcinoma 
metastases.
44
 Clinically lung metastases have been detected in 6% of patients, that has 
exceeded the detection by that observed in autopsy (12%–38%). Clinically, pulmonary 
metastases are usually identified as asymptomatic nodules in the chest x-ray, or can be 
demonstrated as lymphangitic spread associated with pulmonary insufficiency. 
Endobronchial metastases are encountered very rarely. 
Multiple metastatic sites have been recorded by autopsy studies.
45
 Liver metastases 
were among the most frequent of the collective group, which included the gastrointestinal 
tract, kidney, pleura, and adrenal glands. Liver metastases can be detected clinically, 
especially when there is a prostatic primary tumor which  is small cell undifferentiated 
carcinoma. ultimately, multiple other rare sites of metastases of prostatic carcinoma have 
also  been documented in the epididymis, penis, testis, salivary gland, breast, hernia sacs, 
orbit, and skin.
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Earlier days, clinical monitoring of the  distant metastases, particularly bone 
metastases, have been utilizing serum PAP.
47
 Currently, utilization of the  serum PSA has 
replaced such relatively insensitive  and nonspecific  PAP. Indeed, the  serum PSA has 
been utilized for the initial screening of men and still continues to contribute to decide 
upon  to perform the diagnostic biopsy. In Addition, the serum PSA values have been 
employed to monitor the patients, subsequent to definitive surgery or radiation therapy. 
This serum marker has thus been functioning well in both the clinical settings in a vast 
majority of the patients. But, rarely patients with disseminated prostatic carcinoma usually 
do not demonstrate an increase of either serum PSA or PAP.
48
 This is clearly evident both 
at the time of the initial clinical presentation and, also subsequent to radical prostatectomy. 
Among these patients, some also have demonstrated elevated levels of serum NSE, CA19-
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9, CA125, and carcinoembryonic antigen (CEA). Biopsies of  the metastatic sites in these 
patients, have demonstrated a tendency towards the high-grade tumors, the picture of 
small cell neuroendocrine carcinomas, and also  negative immunostaining with PSA 
and/or PAP.  
Awareness of these morphologic and immunohistochemical features in this clinical 
setting will assist in avoiding a potential diagnostic pitfall.
49
 Indeed, it is prudent to 
exclude a prostate primarily in all male patients with a diagnosis of metastatic 
adenocarcinoma of unknown primary site. 
In the study by Aaron.P.Putzke et al, “Expression of E-cadherin was used to 
monitor the epithelial phenotype, and its loss was suggestive of epithelial-mesenchymal 
transition (EMT). EMT triggers tumor metastasis. Exit from EMT was marked by 
increased E-cadherin expression and was considered necessary for tumor growth at the 
sites of metastasis; however, the mechanisms associated with exit from EMT were poorly 
understood. They analyzed 185 prostate cancer metastases, with significantly higher E-
cadherin expression in bone than in lymph node and soft tissue metastases”.4 
The study labelled as  “Expression of e-cadherin in primary and metastatic prostate 
cancer conducted by L.Cheng, M.Nagabhushan, T.P.Pretlow, S.B.Amini and T.G.Pretlow  
demonstrated E-cadherin  in paraffin-embedded whole prostate  tissues and   metastatic 
tissues”.50   
The study by “ Botelho F, Pina F, Lunet N. described as VEGF and prostatic 
cancer: a systematic review, systematical analysis of the evidence on the role of VEGF 
blood concentration in prostate cancer detection was done.
53
 The  Published studies that  
addressed the relation between the  serum or the  plasma VEGF levels and prostate cancer 
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were identified by searching Pubmed, ISI Web of Knowledge, SCOPUS and LILACS up 
to January 2010, and then they were reviewed following a standardized protocol. Three 
studies that reported higher plasma VEGF (pg/ml) in patients having  localized prostate 
cancer than in healthy controls (7.0 vs. 0.0, 9.9 vs. 2.2, and 210 vs. 26.5, P<0.01), and two 
of them showed higher serum VEGF (pg/ml) in prostate cancer patients than in patients 
with benign prostatic hypertrophy (518.9 vs. 267.9, P<0.001; no specific values, P<0.05). 
In one of the  studies, serum VEGF was significantly lower in the healthy controls than in 
those  patients with benign prostatic  hypertrophy, localized or metastatic prostate 
cancer.
52
 The three studies that  had used controls with a  previous suspicion of prostatic 
cancer but, a negative biopsy reported non-statistical significant difference in VEGF 
serum levels (pg/ml) between the controls and the  localized prostate cancer patients (241 
vs. 206; 69.5 vs. 55; 215.2 vs. 266.4). Higher VEGF plasma levels were observed in the  
prostatic cancer patients when compared with healthy controls, but serum levels were not 
useful in differentiating the benign from the malignant prostatic diseases, using, 
individuals as controls, with  high risk of prostate cancer and negative biopsy”.53 
Another study by Michael W. Jackson, Jacqueline M. Bentel, Wayne D. Tilley in 
their publication titled  “Vascular Endothelial Growth Factor (VEGF) Expression in 
Prostate Cancer and Benign Prostatic Hyperplasia” in the journal of urology  analysed the 
presence of  VEGF in well differentiated prostate malignancies and those of normal or 
benign ptostate tissues using the PCR and Western blotting techniques.
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The publication by Simone de Brot et al in Lund University publications titled as 
“Regulation of vascular endothelial growth factor (VEGF) in prostate cancer” observed 
that While radical prostatectomy procedure and radiation have cured many affected, but 
still 30% of the patients  would have suffered either local recurrence or metastatic 
34 
 
disease.
55
 Prostatic carcinogenesis and its transformation would be typically that of an 
testosterone influenced. For the same cause, treatment aimed at recurrent Prostate Cancers, 
target those of “ androgen biosynthesis pathway and the  androgen receptor functions. 
While the androgen deprivation therapies (ADT) were found effective initially, it was 
found that the duration of response has been  typically ≤24 months. While both ADT and 
that of  taxane based chemotherapy, have seem to deliver survival benefits, much of the   
metastatic prostate cancers remain incurable even after that of extensive therapy”. 
When we find out the underlying causes of angiogenesis and the vascular growth 
factors and their regulation, we can resolve a path to the management of organ confined as 
well as distant spread of prostate cancers. “Simone de Brot et al  also enlightened  the 
established mechanisms of transcriptional and the post-transcriptional regulation of VEGF 
in the  prostate cancer cells and further outlined  the molecular insights that were  obtained 
from the  pre-clinical animal models of prostate cancer. Finally, they also  summarized the 
current status  of anti-angiogenesis therapy available for Prostate Cancer and how the 
existing therapies could impact on VEGF signalling”.57 
Thus all these studies emphasise that E-cadherin and VEGF have got essential 
roles to play in the metastatic spread of prostate cancer to distant sites along with several 
other growth factors or transcription factors. 
 Other study by “ Emma Roberts, Davina A. F. Cossigny, and Gerald M. Y. Quan 
in their article titled The Role of Vascular Endothelial Growth Factor in Metastatic 
Prostate Cancer to the Skeleton validate that  the multifaceted effects  that VEGF has on 
the  tumour angiogenesis, the tumour cell proliferation, and the bone destruction, the 
various therapies that  target the VEGF pathways have seem to show much promising 
clinical application and were further  being investigated in the clinical trials.
58
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Traditionally it has been observed that, androgen ablation has been the main mode of  
treatment for the prevention of metastases from prostate cancer. It was thought that these  
prostate cancer cells, initially were dependant on androgens, and thus  suppressing the 
levels of testosterone and dihydrotestosterone decreased the growth rate of prostate cancer 
cells”.5 
But when these hormone influenced cancer cells can also become less sensitive to 
these drugs on the due course and need effective modalities like anti angiogenic factors 
which are on the topic of various studies and researches. They can be proved to be more 
efficient than the toxic radiation and chemotherapeutic modalities.
60 
  “Patient morbidity 
and mortality due to the local tumour recurrence, multimetastatic diseases, loss of 
structural function of  bony skeleton destroyed by the tumour and metastatic epidural 
nerve or spinal cord compression still  remain to be important challenges.
 
The multifaceted effect that VEGF has on tumour angiogenesis, the tumour cell 
proliferation, and the following  bone destruction, newer antiangiogenic therapies that  
target the VEGF pathways have shown much  promising early clinical applications and are 
more  being investigated in the clinical trials. These anti-VEGF therapies include VEGF-
neutralizing antibodies and that of  tyrosine kinase receptor inhibitors. Bevacizumab,  a 
monoclonal IgG1 antibody that is found to  block  the binding of VEGF-A to its receptors,  
by neutralizing all the  VEGF isoforms and the  bioactive  proteolytic fragments through  
the binding of its  antibody Fab-ligand epitope to  Gly88 residue of VEGF. 
61
,
62
 Likewise,  
Aflibercept,  another antibody which is found to  neutralise VEGF and has been currently 
in  use  in Phase II clinical trials for those  patients with recurrence or metastatic urothelial 
cancers.
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 Tyrosine kinase inhibitors act on the VEGF receptors, inhibiting their activation 
following the  ligand binding.
63
  Latest  studies have also suggested that using the  anti-
VEGF therapies such as Bevacizumab in concert with the  radiation therapy or 
chemotherapy might enable in  increasing  the response to radiation therapy. These 
synergistic actions have  also been found  in several preclinical studies and have also 
shown to improve the  rates of survival in those  patients with advanced cancers and that 
of  decreased levels of radiation necrosis”.64 
Drugs that are directed against the receptors of VEGF are found to help in 
achieving quality life, decreasing the  inability of the disease, increasing the survival rates, 
and finally good influence over the disease.
61,62,63,64 
Another study by Deborah Mukherji, Sally Temraz, David Wehbe, Ali 
Shamseddine in their publication “Angiogenesis and anti-angiogenic therapy in prostate 
Cancer” identified that with many upcoming immunological and hormone agents which 
have proved efficacious in various other cancers, still they are of doubtful efficacy in 
prostate cancer. Hence it is aimed to identify anti angiogenic agents that will help us in 
better quality drugs aimed at biological pathways.
65,66
 
 
Also the work done by  Clara Hwang , Elisabeth I Heath named Angiogenesis 
inhibitors in the treatment of prostate cancer, the observation made by  Dr. Judah Folkman 
that tumor cells will be  unable to grow more than 2-3 millimeters if there is no  neo-
vascularization, which lay the foundation for the future in the field of anti-angiogenic 
cancer therapy.
67
 It was also,  observed “ that the process of angiogenesis could be induced  
by a more diffusible substance that is  released by the  tumor cells has  ultimately led to 
the identification of those angiogenic factors which could be identified  for therapeutic 
use. After several decades of investigation, anti-angiogenic agents have thus finally 
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reached the management protocols. The first of these drugs that are FDA-approved like 
bevacizumab, has now been approved for use in colon cancers, renal cancer, breast cancer, 
lung cancer and glioblastoma. But to date, no anti-angiogenic agents have found to be 
approved for their use in the prostate cancer although clinical trials have suggested their 
activity in this disease. Their scope has thus provided an overview of the molecular targets 
that are the key components of the angiogenic signalling”.68 
As the above study, angiogenesis has a key  role  to play  in the development  of 
prostate cancer. Thus angiogenesis inhibitor therapy has been finally evaluated in the 
management of prostate cancer patients. While anti-angiogenic agents appear to have a 
promising inclusion to prostate cancer therapies, there are challenges in clinical trial 
designs and interpretations have prevented the rapid application of these agents into daily 
clinical practice. Among these challenges one among them, certain anti-angiogenic agents 
have been found to increase PSA levels in the face of evidence of disease response. 
 
To meet to this concern, the “2008 Prostate Cancer Clinical Trials Working Group 
(PCWG-2) recommended certain specific endpoints for cytostatic therapies, including the  
anti-angiogenic agents, which emphasize the time-to-event endpoints. Moreover, PCWG-2 
have stressed the importance of radiographic and symptomatic progression while making 
the clinical trial treatment decisions and discouraged the  investigators from discontinuing 
the  treatment on the basis of isolated PSA value elevation. Having such clinical endpoints 
it may thus limit the premature discontinuation of therapy, which have been cited as a 
contributory factor to the negative results of CALGB 90401.
85
 Attention to these 
considerations will help in future clinical development of anti-angiogenic therapy. The 
continued eagerness for anti-angiogenic therapies for  prostate cancer has also been 
justified by the  signs of activity on CALGB 90401, as well as the encouraging phase II 
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data, which includes the combination of bevacizumab and thalidomide with docetaxel. 
Results from several of the  Phase III studies involving the castrate-sensitive, docetaxel-
naïve, and docetaxel-refractory settings are still expected.
70
 Results from these clinical 
trials are expected to clarify the role of these  angiogenesis inhibitors in the arsenal of 
prostate cancer therapies”.68,69 
But still there are no guidelines for managing those patients with higher stages of 
prostate cancer. An equilibrium between the disease subsidence and reduction  of the drug 
toxicity and intolerance of the drug management is also difficult to establish. 
 
 All these research work and studies has aimed at the ultimate of finding a possible 
way to handle the metastatic abilities of prostate cancer and to deal with its complications. 
This study also is one of such studies to enable to identify such cases at early stage, such 
as even when they are asymptomatic by prostate biopsies, the chances of metastasis and 
their possible response to that would be expected to antiangiogenic factors. Thus, in the 
future prospect of prolonging the life of cancer patients with metastases at the earliest 
stage. 
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MATERIALS AND METHODS 
STUDY DESIGN AND MATERIALS 
1. SOURCE OF DATA       : Surgically resected prostate specimens and prostate                           
biopsies, Department of Urology and histopathology laboratory of  Department of 
Pathology 
2. STUDY PLACE               : Coimbatore Medical College and Hospital 
3. STUDY PERIOD             : 12 MONTHS 
4. STUDY DESIGN             : Prospective study 
5. SAMPLE SIZE                : 25 
6. INCLUSION CRITERIA: well fixed and adequate consecutive  specimens of 
prostatic cancer  received in our laboratory during  July 2015 to  June 2016 
7. EXCLUSION CRITERIA: Inappropriately fixed specimens 
                                                         Inadequate specimens 
The detailed clinical history like age, duration of complaints, nature of symptoms, 
haematological and radiological investigations whenever necessary, were collected in all 
cases. All the prostatic specimens were subjected to careful gross examination.  Tissues 
were fixed by10% neutral buffered formalin and routinely processed for paraffin 
embedding. Tissue sections of 4 to 5 micron thickness were cut manually using rotary 
microtome and stained with haematoxylin and eosin for histological typing and grading of 
lesions and slides selected for IHC were coated with gelatin and chrome alum  mixture and 
then subjected for staining for E-cadherin and VEGF. 
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 Gleason’s scoring and grading was done with hematoxylin and eosin stained  
sections and staged histomorphologically. 
IHC Scoring criteria: 
 Glands of prostate with more than 10% cancer cells which showed staining for E-
cadherin and VEGF with DAB chromogen are considered as positive. The scoring is based 
on the expression of staining pattern, intensity and percentage of cells staining positive for 
the chromogen. 
Staining pattern:  
The staining pattern is that area of the tumor cell which takes up the colour to indicate the 
antigen antibody reaction like 
 Membranous 
 Membranous and/ cytoplasmic 
The expression for E-Cadherin is that of membranous and that of VEGF is that of 
cytoplasmic 
Strength of Staining: 
The strength is nothing but the intensity of staining taken up by the antigen antibody 
reaction, which is showed as 
• Weak 
• Moderate 
• Strong staining of the tumor cells. 
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This must also be studied as to whether they are focally present in a few areas or 
are diffusely taken up by almost all the tumor cells in the field under study and the 
percentage of cells stained must be determined as follows. 
Proportion of stained cells: 
• weak---------- <1% cells(negative) 
• 1+----------10-40% 
• 2+----------41-70% 
• 3+----------more than 70% 
This pattern of staining and the intensity of staining is compared with that of Gleason’s 
Scoring and reports were given. 
Results obtained were tabulated and data was analysed with the statistical software 
package. Further observation and results were analysed. 
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OBSERVATION AND RESULTS 
 The current study is about the evaluation of the prostate cancer specimens and the 
value of expression of immunohistochemical markers VEGF and E-cadherin in those 
prostate specimens sent as biopsy or TURP specimens. 
TABLE NO.: 1 INCIDENCE OF PROSTATE LESIONS IN COMPARISON WITH 
ALL SPECIMENS 
PERIOD 
TOTAL NO. OF 
SPECIMENS 
RECEIVED IN 
PATHOLOGY 
DEPARTMENT 
TOTAL NO. 
OF 
PROSTATE 
SPECIMENS 
PERCENTAGE 
July 2015-Dec  2015 2541 51 2.01% 
Jan 2016- June 2016 2645 58 2.19% 
Total 5186 109 2.10% 
 
     A total of 109 prostate specimens (2.10%) were received out of 5186 surgical 
specimens in the Department of Pathology, Coimbatore Medical College, during the 
period of study from July 2015 to June 2016, vide chart no. 1 
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CHART NO.: 1 INCIDENCE OF PROSTATE LESIONS IN COMPARISON WITH 
ALL SPECIMENS 
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TABLE NO. : 2 FREQUENCY OF BENIGN AND MALIGNANT LESIONS 
GROSS BENIGN MALIGNANT TOTAL 
TURP 80 3 83 
TRUCUT 3 23 26 
TOTAL 83(76.14%) 26(23.85%) 109(100%) 
 
PROSTATIC LESIONS: 
Of the 109 total prostate specimens that were received in our Department, in the 
one year period from 2015 to 2016, there were a total of 83 cases that were benign, 
forming 76.14% and malignant cases were about 26 cases forming 23.85% of the total, 
vide chart no.2. 
 NATURE OF THE SPECIMEN: 
Among the benign lesions, 80 cases were from TURP specimens and 3 cases were 
from TRUCUT biopsy specimens. Malignant lesions were diagnosed in 3 TURP samples 
and 23 TRUCUT specimens. 
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CHART NO: 2 FREQUENCIES OF BENIGN AND MALIGNANT LESIONS 
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TABLE NO.:3 INCIDENCE OF PROSTATE CARCINOMA 
PERIOD 
TOTAL NO. 
OF 
SPECIMENS 
TOTAL 
MALIGNANCIES 
PROSTATE 
MALIGNANCIES 
PERCENTAGE 
July 2015-
Dec 2015 
2541 875 12 1.37% 
Jan 2016-
June 2016 
2645 881 14 1.59% 
Total 5186 1756 26 1.48% 
 
Out of the total 5186 specimens received in our Department during the study 
period, malignancies were detected in a total of 1756 specimens in the study period. Of 
which prostate malignancies were about 26 cases forming 1.48% of the total cases vide 
chart no. 3 
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CHART NO.:3 INCIDENCE OF PROSTATE CARCINOMA 
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TABLE NO.:4 INCIDENCE OF PROSTATE CANCER IN GROSS SPECIMENS 
Biopsy n (%) 
Trucut 22 88% 
TURP 3 12% 
Total 25 100% 
 
Of the 25 specimens taken for this study, during the period from july 2015 to june 
2016, prostate cancer was diagnosed in 22 trucut biopsy specimens(88%)  and also 3 of 
the TURP specimens sent with the clinical diagnosis of benign hyperplasia of 
prostate(12%) vide chart no.4.  
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CHART NO.:4 INCIDENCE OF PROSTATE CANCER IN GROSS SPECIMEN 
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TABLE NO.:5 ASSOCIATION OF MEAN AGE WITH CLINICAL DIAGNOSIS 
 
 
95% CI for 
Mean  
 
Mean SD Lower Upper Minimum Maximum Sig 
Ca Prostate 70.2 8.9 66.0 74.4 51 87 
 
BPH 69.2 9.1 57.9 80.5 60 80 >0.05 
Total 70.0 8.7 66.4 73.6 51 87 
 
 
On analysing the age incidence among those patients with benign hyperplasia and 
prostate carcinoma, it was found that the mean age for prostate cancer is 70.2 years and 
that of benign hyperplasia is 69.2 years 
 
 
 
 
 
 
 
 
 
51 
 
 
 
 
TABLE NO.: 6 ANALYSIS OF AGE AMONG THE PROSTATE MALIGNANCIES 
 
 
 
 
 
 
 
Of the total 25 cases of prostate malignancies 28 cases were found in the age group 
of 71-80 years. The youngest individual was 51 years old and the oldest was 87 years old.  
 
 
 
 
 
 
Age Group(YEARS) n (%) 
51 - 60 4 10% 
61 - 70 8 20% 
71 - 80 11 28% 
> 80 Years 2 5% 
Total 25 63% 
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CHART NO.:5 ANALYSIS OF AGE AMONG THE PROSTATE MALIGNANCIES 
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TABLE NO.7 COMPARING THE CLINICAL PRESENTATION 
CLINICAL FINDINGS N (%) 
Back pain 2 8% 
Bone pain 1 4% 
Hard nodular 16 64% 
Hard prostate 1 4% 
Obstructive Uropathy 2 8% 
Urinary Disturbances 3 12% 
Total 25 100% 
 
The final chart shows that a maximum of 64% patients had a hard nodular prostate 
on clinical examination and a minimum of 4% patients had bone pain, indicating 
possibility of bone metastases. This correlates further with MRI/CT scan finding of 8 
cases that was confirmed with radiological evidence of metastasis. 
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CHART NO.:6 COMPARING THE CLINICAL PRESENTATION 
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TABLE NO.:8 INCIDENCE OF METASTASIS WITH MRI FINDINGS 
mri/ct-spine mets n (%) 
present 8 32% 
absent 17 68% 
Total 25 100% 
 
Among the 25 cases that were taken up for study, based on the complaints, the 
clinical findings, and the biochemical values, MRI/CT that was done later during the 
evaluation, showed bony metastatic deposits in 8 of the patients, forming 32% of the n 
number.  
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CHART NO.:7 INCIDENCE OF METASTASIS WITH MRI FINDINGS 
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TABLE NO.:9 COMPARISON OF MEAN PSA WITH BIOPSY 
 
 
 
While comparing the mean PSA values with the form of biopsy specimens sent, 
both the highest and lowest values were with that of trucut biopsy, which had negative 
values as lower confidence limits. Thus the p value is insignificant (>0.05) and nullifying 
the correlation. 
 
 
 
 
 
 
 
 
 
 
 
95% CI for 
Mean  
 
Biopsy Mean SD Lower Upper Minimum Maximum Sig 
PSA Trucut 378.23 897.92 -19.89 776.34 53 4376  
 TURP 168.67 51.00 41.97 295.37 118 220 >0.05 
 Total 353.08 842.93 5.14 701.02 53 4376  
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CHART NO.:8 COMPARISON OF MEAN PSA WITH BIOPSY 
 
 
 
CHART NO.:9 COMPARISON OF MEAN GLEASON’S SCORE WITH BIOPSY 
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TABLE NO.:10 COMPARISON OF MEAN GLEASON’S SCORE WITH BIOPSY  
  
 95% CI for 
Mean 
 
 
Biopsy Mean SD Lower Upper Minimum Maximum Sig 
Gleason's 
score 
Trucut 7.05 0.84 6.67 7.42 5 8 
 
 
TURP 8.33 1.53 4.54 12.13 7 10 <0.05 
 
Total 7.2 1.00 6.79 7.61 5 10 
 
 
 
On comparing the mean of gleason’s score with the form of biopsy specimens,  the 
minimum score was 5 with Trucut and maximum was 10 with TURP,  giving a mean 
value of 7.2. With p value< 0.05, this shows that there is significant association with the 
form of biopsy specimen taken as TURP.   
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TABLE NO.: 11 ASSOCIATION OF MEAN OF GLEASON’S SCORE AND  PSA   
 
 
95% CI for 
Mean  
 
Mean SD Lower Upper Minimum Maximum Sig 
Gleason 
score 
7.2 1.00 6.79 7.61 5 10 
 
PSA 353.08 842.93 5.14 701.02 53 4376 <0.05 
 
On comparing the mean of Gleason score and that of serum PSA levels, which are 
7.2 and 353.08 respectively, there is significant correlation with prostate cancer having a p 
value of <0.05. The maximum Gleason is 10 and that of PSA is 4376pg/ml. With higher 
maximum value of PSA, the confidence limits are set at a wide range between 5.14 and 
701.02pg/ml. 
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CHART NO.: 10 ASSOCIATION OF MEAN OF GLEASON’S SCORE AND PSA 
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CHART NO.:11 COMPARISON OF PSA VALUES AND GLEASON’S SCORE 
 
 
 
It was found that the p value was significant, with <0.05,i.e,  when the Serum PSA 
values and the Gleason’s score, were compared, with significant rise in  PSA levels, the 
Gleason’s scoring also seemed to increase correspondingly in some of the patients. But it 
was also observed that there were also patients with lower PSA levels and slightly higher 
grade of Gleason’s scoring, which shows that there is a correlation with the PSA levels 
and the Gleason’s scoring. 
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TABLE NO.:12 GRADING IHC EXPRESSION OF E-CADHERIN MARKER 
ECADH n (%) 
1+ 14 56% 
2+ 4 16% 
Neg 7 28% 
Total 25 100% 
 
On studying the expression of E-Cadherin in the biopsy specimens, it was found 
that 56% of the cases showed 1+  intensity in staining and about 28% cases showed 
negative staining, indicating the more malignant nature of the cancer in the specimens 
received. 
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CHART NO.:12 GRADING IHC EXPRESSION OF E-CADHERIN MARKER 
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CHART NO.:13 CORRELATION OF E-CADHERIN AND GLEASON’S SCORE 
 
 
 
The scatter diagram shows a linear plot of Gleason’s scoring with that of E-
Cadherin expression with increasing scores mostly seen with 1+ intense expression. 
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CHART NO.:14 CORRELATIONS OF E-CADHERIN AND PSA VALUES 
 
 
The scatter diagram shows that even with minimal elevation of PSA values, the 
expression of E-cadherin tends to become weaker in most of the cases and the case with 
maximum PSA value has negative E-Cadherin expression. 
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TABLE NO.:13 GRADING IHC EXPRESSION OF VEGF MARKER 
VEGF n (%) 
1+ 3 12% 
2+ 12 48% 
3+ 8 32% 
Neg 2 8% 
Total 25 100% 
 
Among the 25 cases studied, maximum number of cases had 2+ intense staining 
forming 48% of cases and 3+ intense staining was appreciated in about 32% of the cases. 
Negative staining was also observed in about 8% of the cases. 
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CHART NO.:15 GRADING IHC EXPRESSION OF VEGF MARKER 
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CHART NO.:16 CORRELATION OF VEGF AND GLEASON’S SCORE 
 
 
 
There is almost a linear plot on comparing the expression of VEGF and Gleason’s 
score, with  a strong expression as the score increases to the maximum of 10(5+5).  
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CHART NO.:17 CORRELATIONS OF VEGF AND SERUM PSA VALUES 
 
 
 
The scatter diagram shows clustering of the expression intensity values with 
increasing PSA values and lower number of negative cases. There is also strong 
expression of VEGF with the maximum PSA value of 4376ng/ml 
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TABLE NO.:14 COMPARISON OF MEAN OF GLEASON WITH VEGF 
 
 
95% CI for 
Mean  
 
VEGF Mean SD Lower Upper Minimum Maximum Sig 
Gleason 
 score 
1+ 6.3 1.2 3.5 9.2 5 7 
 
 
2+ 6.9 0.7 6.5 7.3 6 8 
 
 
3+ 8.0 1.1 7.1 8.9 6 10 
 
 
NIL 7.0 0.0 7.0 7.0 7 7 <0.05 
 
Total 7.2 1.0 6.8 7.6 5 10 
 
 
On comparing the mean value of Gleason score and the expression of VEGF, it 
was found that, there was increased and strong expression of VEGF with increasing 
scores. The maximum score of 10 showed intense 3+ positivity and the minimum score of 
5 showed 1+ positive staining with a significant p value of<0.05. 
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CHART NO.:18 COMPARISON OF MEAN OF GLEASON WITH VEGF 
 
CHART NO.: 19 COMPARISON OF MEAN OF PSA WITH VEGF EXPRESSION 
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TABLE NO.:15 COMPARISON OF MEAN OF PSA WITH VEGF EXPRESSION 
 
95% CI for 
Mean  
 
VEGF Mean SD Lower Upper Minimum Maximum Sig 
PSA 1+ 118.3 47.1 1.4 235.2 64 146 
 
 
2+ 175.3 73.5 128.6 222.1 53 285 
 
 
3+ 758.3 1466.2 -467.6 1984.1 53 4376 
 
 
NIL 151.0 7.1 87.5 214.5 146 156 >0.05 
 
Total 353.1 842.9 5.1 701.0 53 4376 
 
 
The analysis of the comparison between PSA values and that of VEGF expression 
show that, though there was intense 3+ positivity with the maximum value of 4376ng/ml, 
there was also intense 3+ positivity with a minimum value of 53ng/ml. this gives us a nil 
significant p value of >0.05. 
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TABLE NO.:16 CORRELATIONS OF VEGF AND E-CADHERIN EXPRESSION 
IN PROSTATE CANCER 
  
Upon analysis of the expression of VEGF and E-Cadherin IHC markers, it was 
found that 28% of the cases had 3+ intense staining with VEGF and the same cases had 
negative staining with E-Cadherin.  It has also been  observed that there were no cases 
having negative staining with VEGF and high intense staining with E-cadherin, ruling out 
the benignity of the cases. But very few cases had weak 2+ staining of both the markers. 
 
 
 
 
 
 
 VEGF  
ECADH 1+ 2+ 3+ Neg Total (%) 
1+ 3 8 1 2 14 56% 
2+ 0 2 2 0 4 16% 
Neg 0 2 5 0 7 28% 
Total 3 12 8 2 25 100% 
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CHART NO.:20 CORRELATIONS OF VEGF AND E-CADHERIN EXPRESSION 
IN PROSTATE CANCER 
 
 
Analysis of statistical data:         
The data have been  reported as the mean +/-  SD or  the median, depending on their 
variable distribution.         
Frequencies are expressed in percentages.       
The differences that were observed among the quantitative variables between the groups 
were assessed by utilising the unpaired t test.  
Comparsion between groups was made by the Non parameteric Mann - whitney test 
ANOVA was performed.         
The chi square test was utilised to assess the  differences in the  categoric variables 
between  the various groups.         
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A p value of <0.05 while using a two-tailed test has been  taken as being of significance 
for all statistical tests. 
 All data were analysed using the statistical software  package .(SPSS, version 16.0 for 
windows)         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
COLOUR PLATES 
 
 FIG.1 Benign prostatic hyperplasia H&E-40X 
 
                       FIG.2 BPH E-cadherin Weak 2+ positivity -10X 
 
 FIG. 3 BPH VEGF Negative Staining-10X 
            
 
 
 
 
 
 
 
FIG. 4 Prostate adenocarcinoma– Gleason score 6 H&E-40X 
  
 
                      
 
 
 
FIG.5 PAC– Gleason score 6 E-cadherin Negative staining -10X 
  
                   
                
 
 
 
 
 
FIG. 6 PAC– Gleason score 6 VEGF Strong 3+ positivity -40X 
                            
 
 
 
 
 
 
 
FIG. 7 PAC– Gleason score 10 -H&E-40X 
 
FIG. 8 PAC– Gleason score 10 E-cadherin Weak 2+ positivity -10X 
 
                        FIG. 9 PAC– Gleason score 10 VEGF Strong 3+ positivity -40X 
 
FIG. 10 PAC– Gleason score 7 -H&E-40X 
 
 
 FIG. 11 PAC– Gleason score 7 E-cadherin Weak 2+ positivity -40X 
 
FIG. 12 PAC– Gleason score 7 VEGF Strong 2+ positivity -40X 
 
                
 
 
 
 
FIG. 13 PAC– Gleason score 8 E-cadherin Strong 2+ positivity -40X 
 
                        
 
 
 
 
 
 
FIG. 14 PAC– Gleason score 8 VEGF Strong 3+ positivity  - 40X 
 
 
 FIG. 15 PAC– Gleason score 7 E-cadherin  Negative -10X 
 
 
FIG. 16 PAC– Gleason score 7 VEGF Strong 2+ positivity -40X 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
As per the National Cancer Registry Programme, the Population Based Cancer 
Registry (PBCR), has released reports for the last three years as,  Bangalore -APC: 2.82%, 
Chennai -4.13%, Delhi -3.36% and Mumbai -1.17% recording a statistically significant 
increase in the trend in the  incidence rates over time.
1
 The most recent PBCR ‘s of the 
different cities in our country show that prostate cancer has been ranked among the top ten 
leading sites of cancer in many the largest cities in the country.  
 
The incidence rates in various cities of our country is shown in the above table. On 
comparing with the national statistics, the incidence in our study for a period of one year is 
1.48%, which is in conjunction with other cities. 
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TABLE NO.17 
COMPARISON OF INCIDENCE OF PROSTATE CARCINOMA IN INDIA 
S.NO NAME AND YEAR OF STUDY PREVALENCE 
1. Population based cancer registry-Delhi 2012-2014 12.4% 
2. 
Population based cancer registry-Kamrup urban district 
2012-2014 
12.2% 
3. Population based cancer registry-Mumbai 2012-2014 9.8% 
4. Population based cancer registry-Bangalore 2012-2014 8.2% 
5. Population based cancer registry-Tripura 2012-2014 1% 
6. Population based cancer registry-Chennai 2012-2014 6.7% 
7. Present study in Coimbatore 2015-2016 1.48% 
 
Early diagnosis, detection and management before the tumor metastasises, is 
critical for improving patient survival. Most cases of cancer prostate, present with organ 
confined cancer and are managed with procedures like surgery, radiation or androgens. 
But, the truth is, like most of the solid malignancies, establishment  of metastatic tumor 
sites  is ultimately lethal. Despite newer  therapeutic modalities available systemically, 
metastatic phenotype is characterised by unchangeable  development of resistance, disease 
stage  progression and death, ultimately. 
             The 5 year survival rate has been found to be high in case of organ confined 
prostate cancers, but when there are metastatic deposits, the same gets reduced to about 
33%
58
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In various studies it had been found that with radical prostatectomy specimens, 
done for organ confined prostate cancers, 17% had extra-prostatic extension that was 
detected later.  
Likewise in the current study, where of the 25 cases taken for study, nearly 32% 
had suspicious extra prostatic extension that was identified by immunohistochemical 
studies done in the trucut biopsies received. 
Currently, new pathologically important prognostic factors are being investigated 
like, Ki67, p53, microvessel density, etc. but better biomarkers of disease progression like 
angiogenesis factors, will be useful in predicting the progression or prognosis. 
Tumor cells are stimulated by angiogenic factors to result in angiogenesis and 
nodal metastasis associated with bone marrow metastasis. Tumor cells without nutritional 
factors, oxygen or angiogenic factors cannot survive beyond 2-3 mm of dimension, 
anywhere. 
One of the factors induced by hypoxia, leading to the formation of 
neovascularisation is VEGF-Vascular Endothelial Growth Factor, whose expression 
closely relates with advanced progression of the disease state- particularly malignancy.
71
 
VEGF stimulates angiogenesis and increases microvessel density, indirectly stimulating 
tumor growth and prostate cancer elsewhere from the primary tumor site. 
Earlier studies were controversial that benign conditions had more expression of 
VEGF. But current and recent studies  by Wu et al, in their work on Benign and malignant 
prostatic epithelium, they detected a vast difference in the VEGF immunoreactivity by 
tumor cells of prostate- which is contrary to the older studies.
72
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 Also, in the study by Jose luis et al, on plasma levels of VEGF in patients with 
metastatic prostate cancer, it was confirmed that the median level of plasma VEGF  was 
28.5pg/ml in patients with metastasis.
73
 While the same was about 7pg/ml in patients with 
localised disease and 0pg/ml in normal disease free controls. This statistically significant 
difference gave the conclusion that plasma “VEGF levels are higher in patients with 
metastatic prostate cancer, than those with localised disease or healthy individuals”.73 
TABLE NO.:18 
COMPARISON BETWEEN THE CURRENT STUDY AND STUDY BY  
JOSE ET AL 
VARIANTS JOSE ET AL CURRENT STUDY 
Total no. of 
specimens 
80 25 
Organ confined cases 54 17 
With metastasis 26 8 
Method of VEGF 
assessment 
Plasma level immunohistochemical 
significance <0.001 <0.005 
  
Similarly in the study by Aaron.P.Putzke et al the frequency of E-Cadherin 
expression in a large cohort of metastatic prostate cancer was analysed. E-Cadherin 
expression was measured  in a cohort of 185 prostate cancer patients, using HECD1 
Antibody binding to the epitope of E-Cadherin which is extracellular and,  which showed 
that 109 patients had bone and 56 had soft tissue metastases. In the metastatic tissues, E-
Cadherin expression ranged from virtually no staining to intense staining showing a strong 
correlation between membrane and cytoplasmic E-Cadherin immunoreactivity(p<0.01)
4
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   The study by Hiroki Kuniyasu et al in the year 2000 concluded that there was “ 
lower expression of E-Cadherin in advanced tumors and higher expression of  
VEGF/VPF, MMP-2 and MMP-9 in advanced tumors than organ confined tumors.
3
 The 
expression of metastasis related genes were also studied in comparison with the Gleason’s 
score. This showed that high grade, poorly differentiated tumors expressed a lower level of 
E-Cadherin m-RNA(p<0.01) and a higher level of VEGF/VPF mRNA(p=0.15) than 
tumors with Gleason score 5-6 tumors”.3  
They also observed that “ tumors of  higher pathological stage exhibited higher 
VEGF/VPF expression levels than tumors of low pathological stage”. They also concluded 
that “ tumors with Gleason score<6 were mostly found to be organ confined, whereas 
those with Gleason score >8 were associated with extra-prostatic disease and thereby had 
poor prognosis”.74 
  Another study by L.Cheng and M.Nagabhushan, on Expression of  E-Cadherin in 
primary and metastatic prostate cancer, 53 primary prostate cancers and 14 patients with 
metastases were taken up for study. Among the organ confined prostate cancer patients a 
maximum of 21 patients had moderate staining of E-Cadherin and others had 
heterogenous expression. But the expression was decreased in the poorly differentiated 
cases as well as when the Gleason increased, the expression of E-Cadherin 
declined(p=0.03). “Among the patients with metastases 86% of them showed negative or 
weak expression of E-Cadherin. The expression of E-Cadherin in metastatic prostate 
cancer was reduced compared with that in primary prostate cancer”.50  
Finally, it was concluded in their study that the “expression of E-Cadherin is 
decreased in less well differentiated prostate cancers and in metastases”. 
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TABLE NO.:19 
COMPARISON OF EXPRESSION OF E-CADHERIN BETWEEN PRIMARY 
PROSTATE CANCER AND METASTASES IN THE TWO STUDIES 
 
L.CHENG ET AL 
STUDY 
THIS STUDY 
E-Cadherin 
Primary 
prostate 
Metastases 
Primary 
prostate 
Metastases 
NEGATIVE 7 8 3 4 
1+ 16 4 13 1 
2+ 21 2 1 3 
3+ 9 0 0 0 
TOTAL 53 14 17 8 
 
  The study by Erem.K.Basok, et al titled “Prognostic value of 
immunohistochemical expression of VEGF, E-Cadherin and BIM in radical prostatectomy 
specimens  in the year 2009, included 66 cases of radical prostatectomy for prostate 
cancer. The expression of VEGF was found to be increased in about 59.74% of patients 
with biochemical recurrence and 44.47% patients without biochemical 
recurrence(p=0.05)
75
 giving a significant correlation between  expression of VEGF and E-
Cadherin”.74,75 
    Similarly the study on “ VEGF expression in human prostate cancer: in situ and 
in vitro expression of VEGF by human prostate cancer cells by Fernando A.Ferrer  
demonstrated that in 20 of 25 specimens, prostate cancer cells stained positively for 
VEGF. BPH and normal prostate cells displayed little staining for VEGF”.76 So, they 
concluded that significant  expression was present with VEGF in prostate cancer, but not 
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with BPH or normal prostate cells invivo. The invitro studies showed a differential 
regulation of angiogenesis factor expression in prostate malignancy. Hence identifying 
these angiogenic factors that are involved in cancer growth and a better understanding of 
their regulation will lead us to the development of necessary anti-angiogenic modalities 
useful for diagnostic and therapeutic interventions”.76 
According to a study by Yasuhide Kitagawa, et al, in their study titled “Vascular 
endothelial Growth Factor contributes to prostate cancer mediated osteoblastic activity, 
Prostate cancer cells expressed the mRNA for VEGF receptor (VEGFR) neuropilin-1. 
Therefore osteoblastic nature of the metastases is in some way attributed by the VEGF 
receptors”.77 
 Another study titled, “Metastatic properties of prostate cancer cells are controlled 
by VEGF done by Chen J, De S, Brainard J, Byzova TV concluded that prostate cancer 
cells expressed Vascular endothelial growth factor (VEGF), its receptors (VEGFRs)   and 
alpha5beta1 integrin, in vitro and by the same  prostate tumors in vivo.
78
 The  expression 
of these factors were  elevated at the  sites of bone metastasis when compared to the  
original prostate tumor itself. VEGF, by means of interaction with its receptors, it 
regulated the adhesive and migratory properties of these cancer cells. More specifically, it 
was found that the highly metastatic prostate cancer cell subline like LNCaP-C4-2 also  
showed a decreased adhesive but  enhanced migratory response to  the fibronectin, a 
ligand, for alpha5beta1 integrin, when compared to its nonmetastatic counterpart. It was 
also found out that the  increased migration of metastatic prostate cancer cells to the 
fibronectin and the bone sialoprotein were regulated by VEGF through VEGFR-2.
79
 And 
tumor suppressor PTEN was also found to be involved in control of VEGF/VEGFR-2 
stimulated  adhesion and proliferation of prostate cancer cells”.78,79 
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 Also in the study “Vascular Endothelial Growth Factor (VEGF) Expression in 
Prostate Cancer and Benign Prostatic Hyperplasia byMichael W. Jackson, Jacqueline M. 
Bentel, Wayne D. Tilley, where they studied the immunohistochemical localisation of 
VEGF in both malignant and non-malignant conditions of prostate.
54
 They finalised that 
there was  widespread distribution of VEGF receptors in the prostate cancers and also the 
BPH specimens suggesting that the VEGF165, VEGF189 isoforms and the novel 90 and 
110 kD forms , when detected may contribute to the authentic establishment or 
progression of these conditions”.54 
The current study shows that there is an equal incidence in prostate cancer in 
accordance with the national cancer registry. Also the Gleason score and the serum PSA 
values are also significantly correlating with the clinical diagnosis of prostate cancer and 
with extra- prostatic extension. 
Immunohistochemical analysis always has been a valid aide in the diagnosis or 
exclusion of prostate carcinoma in doubtful cases. This in addition will help us in keeping 
a step forward by diagnosing advanced stages of prostate cancer using 
immunohistochemical markers like VEGF and E-Cadherin, which are important predictors 
of metastases or progression, as proved by various studies stated above. Thus in 
conjunction with such studies, the present study has also shown that there is loss of E-
Cadherin expression in cases of advanced malignancy stages in contrast to the benign 
conditions like benign hyperplasia of prostate, where there will be moderate to strong 
expression in the glandular cells. 
 Also it is observed that there is increased VEGF expression in most of the prostate 
cancer specimens analysed and that there is still strong expression in some cases with 
suspicious extra prostatic extension than those of organ confined cases. Of the 8 cases with 
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suspected extra prostatic extension, only 1 case showed 2+(moderate) intense staining 
pattern and all the remaining 7 cases showed 3+(strong) staining pattern. This is 
accordance with the various other studies done worldwide, proving the correlation 
between metastases and vascular factor, being a cause for the easy spread of the tumor to 
distant sites away from the primary. 
                   So, as per the study by Clara Hwang and Elisabeth I Heath in their review 
article titled, “Angiogenesis inhibitors in the treatment of prostate cancer”, inhibition of 
angiogenesis can be made one of the relatively novel anti –neoplastic approaches, which 
can target the dependance of tumor growth on the formation of newer blood vessels. The 
same strategy has been in use successfully in other cases of solid tumor types like breast, 
lung, colon,etc.”80 A similar situation is not far, for treating prostate cancers with extra 
prostatic extension, as studies are already on with antiangiogenic therapies, targeting the 
organs. 
  The  conclusion of the research article titled,  “Prognostic value of Vascular 
Endothelial Growth Factor expression in patients with prostate cancer: a systematic review 
with meta-analysis, by Kai Wang, Hong-Ling Peng and Long-Kun Li, states that VEGF 
can be regarded as a better prognostic marker for prostate cancer as per their meta-
analysis”.81 “But to achieve a more definitive conclusion enabling the clinical use of 
VEGF in prostate cancer, we need more high quality interventional original studies 
following agreed research approaches or standards” and the same is emphasised. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION 
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SUMMARY 
 In the present prospective study, consisting of 25 cases of prostatic cancer 
specimens that were received in our department,  histopathological analysis, 
immunohistochemical analysis of the expression of the markers,  VEGF and E-cadherin 
was done in the  period from July 2015 to June 2016. The following are the salient 
observations noted in the study. 
1. Prostatic specimens constituted 2.10% of the total number of surgical specimens 
received in the same period. 
2. Of them, 76.14% specimens were benign in nature and the remaining 23.85% were 
malignant cases. 
3. Of all the malignant lesions that were reported in the department, prostate 
malignancies constituted about 1.48%. 
4. Regarding the nature of the specimens, majority were trucut biopsies forming 88%, 
but cancer prostate was also diagnosed in 12% of the specimens sent as TURP, 
which were suspected to have benign hyperplasia of prostate. 
5. The mean age for presentation of cancer prostate is 70.2 years and that for benign 
prostate hyperplasia is 69.2 years. 
6. The peak age group of occurrence of cancer prostate in the study is found to be 70 
to 80 years. 
7. Regarding the clinical presentation, majority of patients 64% presented with hard 
nodular prostate, without any major symptoms. About 8% and 12% patients had 
obstructive uropathy and other forms of urinary disturbances, respectively. Only 
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<5% of patients had suspicious symptoms of metastases like back pain and bone 
pain. 
8. There is significant correlation between Gleason’s score and PSA in relation with 
cancer prostate with p value<0.05, with increase in Gleason score, PSA is also 
found to be increased. 
9. There is a positive correlation between the mean values of PSA and Gleason score, 
as the PSA values increase, the Gleason score is also seen to increase in the cases 
studied. 
10. There is significant correlation between Gleason score and trucut biopsy having a p 
value of<0.05, but not the same with serum PSA and the nature of the specimen,  
giving a p value of>0.05. 
11. The expression of  E-Cadherin is lost in about 28% of the cases, whereas in a 
majority of 56% of the cases showed weak or moderate positivity. E-cadherin 
expression in poorly differentiated prostate cancer with Gleason  score>7 was 
reduced, while in well differentiated prostate cancer with Gleason score <7, was 
increased. This indicates that as the differentiation becomes poorer, E-cadherin 
expression is also lost. Thus the cells lose their intercellular adhesion, are more 
separated and are ready to metastasise. Thus the E-cadherin expression decreases, 
the occurrence of metastasis would increase. 
12. The expression of VEGF was strong in a majority of 48% of cases and negative 
staining was observed in a minimum of 8% of cases.VEGF expression was low in 
well differentiated prostate cancer with Gleason score <7, while it was high in 
poorly differentiated prostate cancer with Gleason score>7 with a p value 
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<0.05(significant correlation).thus as the malignancy increases, angiogenesis 
increases. 
13. There is definite correlation between the expression of VEGF and E-Cadherin with 
a p value of <0.05, indicating that with progression of the disease, there is loss of 
expression of E-Cadherin and increased expression of VEGF. 
14. There is no significant correlation between the expression of E-Cadherin in 
comparison with Gleason score and serum PSA values (pvalue>0.05). 
15. But, there is significant correlation in the expression of VEGF in comparison with 
Gleason score, confirming that with progression of the disease all these parameters 
are elevated(p value<0.05). 
16. The same does not go with PSA values and VEGF, as the PSA values are elevated 
in benign lesions also and there is no significant correlation, p value>0.05. 
 
 
 
 
 
 
 
 
89 
 
CONCLUSION 
  To conclude, it is found that there is significant number of  incidence of prostate 
cancer with extraprostatic extension, without any major symptoms. So, in such cases the 
utilisation of these easily available markers like VEGF and E-Cadherin, even in minimal 
amount of tissue like trucut biopsy specimens, will help us to anticipate the progression of 
the disease to advanced stages, without using  any other serum markers. The 
histopathological  analysis of the entire prostate and henceforth characterisation of the 
worst cancers are always critical.  
Prostate carcinoma is increasing in incidence and with the advent of innovative 
diagnostic techniques, it is identified at an early stage. However patients with metastases 
are also still persisting. This cautions us towards finding a serological marker or any other 
diagnostic method along with PSA for a mass screening program in the geriatric age 
group. 
Also E-cadherin expression could be analysed routinely in all prostatic cancer 
biopsy specimens to enable early detection of bad prognosis and to follow a more 
scrupulous follow up in the treatment strategy of such patient. 
VEGF expression is increased with increase in the degree of malignancy. Thus, 
angiogenesis is to be targeted with newer drugs to control the spread. 
 Further studies with ample sample size and involving more patients is suggested 
to confirm the diagnostic utility and predict prognosis using E-cadherin and VEGF. 
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ANNEXURES 
 
ANNEXURE I 
PROCEDURE OF IMMUNOHISTOCHEMICAL STAINING 
Principles of the procedure: 
First the coated slides with the tissue sections are incubated at 37 degrees Celsius 
overnight, so that they are dewaxed. Sections are then deparaffinised in xylene for 30 minutes 
and rehydrated through graded alcohols to distilled water. Antigens present in the tissues and 
the cells can be detected by a two step process: first the primary antibody must bind to the 
corresponding specific epitope of the antigen and then this antigen-antibody reaction is 
detected by coloring reagent which does not affect the antigen- antibody reaction. 
Peroxidase and anti- peroxidase method and 3,3-diaminobenzidene(DAB) Chromogen 
are applied for immunohistochemical analysis. Endogenous peroxidase activity blocked with 
0.6% hydrogen peroxide. 
Antigen retrieval was done using microwave by incubating the slides in 10mmol/L 
Citrate buffer for E-Cadherin with a pH of 6 and 10mmol/L TRIS EDTA buffer with a pH of 
9, for VEGF antibodies, respectively. After blocking, sections are incubated at room 
temperature for 1 hour with antibodies to E-cadherin and VEGF which are monoclonal 
mouse antibodies. 
  After treatment with antibodies, the slides were rinsed with tris buffer solution and 
treated with horse radish peroxidase label at room temperature for about 30minutes. Again 
the slides were rinsed with tris buffer solution and treated with DAB chromogen and 
hematoxylin for counter staining. 
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REAGENTS USED: 
1. Peroxide block 0.6% hydrogen peroxide in water 
2. Primary antibody- monoclonal mouse antibody to E-Cadherin and VEGF 
3. Poly-HRP label 
4. Chromogen :DAB-3,3’-Diaminobenzidine 
5. Liquid DAB substrate with buffer and peroxide stabilisers 
6. Counter stain: Ehrlich’s  hematoxylin 
7. Buffer solutions: 
TRIS BUFFER: (PH.-7.6) 
TRIS buffer salt:0.605 gm 
Sodium chloride:8 gm 
Distilled water:1000 ml 
1N Hydrochloric acid:3ml 
 CITRATE BUFFER:(Ph-6.0) 
Trisodium citrate: 2.94 gm 
Distilled water : 1000ml 
1N hydrochloric acid: 5ml 
 TRIS –EDTA BUFFER:(Ph-9.0) 
TRIS buffer salt: 6.05 gm 
Disodium EDTA: 0.744 gm 
Distilled water: 1000 ml 
PROCEDURE: 
1. Sections are deparaffinised in xylene for 30 minutes. 
2. Sections are then treated in absolute alcohol for 15 minutes. 
3. Then the sections are washed in tap water for 5 minutes. 
4. Sections are placed in distilled water for 5 minutes. 
5. Antigen retrieval is proceeded by placing the slides in the corresponding buffer 
solutions in microwave and heated at 450kw for 10 minutes and at 800kw for 10 
minutes. 
6. Sections are then cooled to room temperature and rinsed in distilled water. 
7. The slides are wiped dry around the sections and placed in peroxide block for 10 
minutes.  
8. The sections are rinsed in distilled water and then washed in tris buffer solution twice 
for about 2 minutes. 
9. Sections are wiped around and treated with primary antibody, correspondingly 
(supplied from BIO SD) for 1hour. 
10. The sections are again washed in tris buffer solution. 
11. HRP label is then added to the sections for 30 minutes. 
12. Again the slides are washed with tris buffer solution twice. 
13. Then DAB chromogen along with substrate buffer is added to the sections for 5 to 8 
minutes, which enhances the antigen antibody reaction giving a brown colour to the 
reaction. The same solution has to be used with caution as it is highly carcinogenic. 
14. Sections are then washed with Tris buffer solution twice. 
15. Slides are washed in distilled water for 5 minutes 
16. Counterstaining with Ehrlich’s  Hematoxylin for 1 minute. 
17. Washed with tap water for 5 minute. 
18. Air dried and mounted with DPX. 
 Tumor cells are counted as positive when they show brown colour in their membrane or 
cytoplasm.  
ANNEXURE II 
PROFORMA 
Coimbatore medical college 
Department of   Pathology 
Coimbatore 
Particulars of the patient: 
Name  :                                                          Age: 
Ward    :                                                       IP. No : 
Address:                                                       Occupation: 
 Presenting complaints: 
Urinary symptoms-frequency    hematuria 
                                Urgency    dysuria 
                                 Strangury    retention 
                                Nocturia    hesitancy 
General symptoms- loss of weight, loss of appetite,  Back ache, headache, fractures, 
weakness  
Past history:h/o any surgery for prostate enlargement 
Family history 
Personal history: 
Diet 
General examination:              
Nourishment :                    Built:                                              Conscious:        
Pallor:                                 Jaundice:                                         Clubbing: 
Febrile/afebrile                    Lymphadenopathy :                        Edema: 
Tremors:                             eye signs: 
Vitals: 
Pulse rate:                     BP:                RR:       
Per abdomen: bladder distension, local bone tenderness       
Per rectal: Digital rectal examination, sphincter tone,  
 Clinical diagnosis: 
Investigations: 
USG/TRUS report 
Serum PSA 
Serum creatinine 
Chest Xray, LFT 
 
MRI FINDINGS 
TRUS guided biopsy of prostate 
Microscopic findings: 
Histopathological diagnosis 
Immunohistochemistry: 
FINAL DIAGNOSIS 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
Dr.V.Nithyananthinie, postgraduate student in the Department of Pathology, 
Coimbatore Medical College is conducting a study on “THE VALUE OF EXPRESSION 
OF–E-CADHERIN AND VEGF IMMUNOHISTOCHEMICAL MARKERS IN PROSTATE 
CARCINOMAS”. Prostate biopsy done for detecting prostate carcinoma or benign 
hyperplasia of prostate are received in pathology department and are processed and examined 
under a microscope to obtain diagnostic information or is tested for other studies.  I have 
been informed, to my satisfaction regarding the nature of surgical procedure. The data used 
herein may be used for research and publication.  
 
 
Name:  
Place: 
Signature: 
 
 
 
 
 
 
 
 
xg;g[jy; gotk; 
 
bgah;   : 
taJ   : 
ghypdk;  : 
Kfthp  :  
 muR nfhit kUj;Jtf; fy;Y}hpapy; neha; Fwpapay; kUj]Jt Jiwapy; 
gl;;l nkw;gog;g[ gapYk; khztp kU. tp. epj]ahee]jpdp mth;fs; nkw;bfhs;Sk;            
“E-Cadherin kw]Wk] VEGF –  fhuzpfisf] bfhz]L g]uh!]nll] g[w]Wnehapd] 
jd]ikia fz]lwpjy]” gw]wpa Ma]t[ kw;Wk; midj;J tpsf;f';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. 
 
 ehd] ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J bfhs;s 
rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd]id gw;wpa midj;J tptu';fs; ghJfhf;fg;gLtJld; 
,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpy; ,Ue;J ehd] tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk; : 
njjp :                    nehahspapd] ifbahg;gk; / nuif 
ANNEXURE-III 
ABBREVIATIONS 
VEGF  - Vascular Endothelial Growth Factor 
PSA  -  Prostate Specific Antigen 
PBCR  - Population Based Cancer Registry 
TURP  - TransUrethral Resection of Prostate 
BPH  - Benign Prostatic Hyperplasia 
PSMA  - Prostate Specific Membrane Antigen 
PAP  - Prostatic Acid Phosphatase 
RT-PCR - Reverse Transcriptase Polymerase Chain Reaction 
ISH  -  In Situ Hybridisation 
mRNA  - micro-Ribo Nucleic Acid 
MVD  - Micro Vessel Density 
bFGF  - Basic Fibroblast Growth Factor 
PDGF  -  Platelet Derived Growth F actor 
TNM  - Tumor Node Metastasis 
AJCC  - American Joint Committee on Cancer 
EMT  - Epithelial Mesenchymal Transition 
ADT  - Androgen Deprivation Therapies 
DAB  - 3, 3`DiAmino Benzidene 
MMP  - Matrix MetalloProteinase 
HRP  - Horse Radish Per Oxidase 
 
  
SL. 
NO. 
HPE 
NO. 
AGE/S
EX 
IP NO. 
CL. 
Diagnosis 
HPE 
Diagnosis 
Gl. 
grade 
Gl. 
score 
PSA 
Nature of 
biopsy 
MRI/ 
CT 
ECAD VEGF CL.finding 
1 910/15 76/M 19381 BPH PAC 3+4 7 168 TURP NIL 1+ 2+ OU 
2 942/15 80/M 20317 BPH PAC 5+3 8 220 TURP SPINE M NEG 3+ UD 
3 1268/15 75/M 26042 CA.PROST. PAC 3+4 7 146 TRUCUT NIL 1+ NEG HN 
4 1310/15 60/M 25109 BPH PAC 5+5 10 118 TURP SPINE M 2+ 3+ HP 
5 1540/15 72/M 70887 CA.PROST. PAC 4+4 8 380 TRUCUT SPINE M NEG 3+ HN 
6 1946/15 82/M 40428 CA.PROST. PAC 3+4 7 156 TRUCUT NIL 1+ NEG HN 
7 2172/15 72/M 44693 CA.PROST. PAC 3+3 6 120 TRUCUT NIL 2+ 2+ HN 
8 2389/15 60/M 48121 BPH PAC 3+3 6 53 TRUCUT NIL 1+ 2+ OU 
9 2512/15 70/M 51670 BPH PAC 4+3 7 243 TRUCUT NIL 1+ 2+ UD 
10 2809/15 71/M 56280 CA.PROST. PAC 4+4 8 4376 TRUCUT SPINE M NEG 3+ HN 
11 3218/15 75/M 64783 CA.PROST. PAC 4+3 7 175 TRUCUT NIL 1+ 2+ HN 
12 3835/15 55/M 79855 CA.PROST. PAC 4+4 8 360 TRUCUT SPINE M 2+ 3+ HN 
13 178/16 63/M 4052 CA.PROST. PAC 3+3 6 53 TRUCUT NIL NEG 3+ HN 
14 335/16 87/M 8012 CA.PROST. PAC 3+4 7 146 TRUCUT NIL 1+ 1+ HN 
ANNEXURE IV 
MASTER CHART 
  
15 566/16 74/M 10357 CA.PROST. PAC 4+3 7 178 TRUCUT NIL NEG 2+ HN 
16 654/16 51/M 12107 CA.PROST. PAC 4+4 8 213 TRUCUT NIL 1+ 2+ HN 
17 691/16 68/M 14357 CA.PROST. PAC 4+3 7 285 TRUCUT NIL NEG 2+ HN 
18 1005/16 76/M 17645 CA.PROST. PAC 4+4 8 324 TRUCUT SPINE M NEG 3+ BACKACH 
19 1111/16 62/M 21472 CA.PROST. PAC 3+2 5 145 TRUCUT NIL 1+ 1+ BACKACH 
20 1251/16 80/M 24533 CA.PROST. PAC 4+4 8 280 TRUCUT SPINE M 2+ 2+ UD 
21 1493/16 68/M 26682 CA.PROST. PAC 4+4 8 235 TRUCUT SPINE M 1+ 3+ BP 
22 1937/16 64/M 38255 CA.PROST. PAC 4+3 7 126 TRUCUT NIL 1+ 2+ HN 
23 2073/16 70/M 41014 CA.PROST. PAC 3+4 7 64 TRUCUT NIL 1+ 1+ HN 
24 2118/16 77/M 41525 CA.PROST. PAC 3+3 6 76 TRUCUT NIL 1+ 2+ HN 
25 2146/16 62/M 41867 CA.PROST. PAC 4+3 7 187 TRUCUT NIL 1+ 2+ HN 
 KEY WORDS 
BPH  - Benign Prostatic Hyperplasia 
PAC  - Prostate AdenoCarcinoma 
Gl. Grade - Gleason Grade 
PSA  - Prostate Specific Antigen 
TURP  - TransUrethral Resection of Prostate 
HN  - Hard Nodular prostate 
HP  - Hard Prostate 
OU  - Obstructive Uropathy 
UD  - Urinary Disturbance 
BP  - Bone Pain  
 
